Penumbra Inc

Penumbra is a U.S.-based medical device company focused on thrombectomy and related interventional therapies for removing blood clots from the body. Its portfolio spans products used in ischemic stroke, pulmonary embolism, acute limb ischemia, embolization, and vascular access, and it sells through direct commercial teams and distributors across the United States and international markets.

14,7 %

67,1 %

12,7 %

+17,5 %

6.64

4.29

— Penumbra Inc
%
Thrombectomy systems55% Devices and systems used to remove blood clots in stroke, PE, and limb ischemia.
Neurovascular products20% Products used by specialists treating ischemic stroke and other neurovascular conditions.
Vascular access and embolization15% Tools for accessing vessels and treating vascular abnormalities or bleeding.
Other interventional products10% Adjunct products and newer offerings supporting the broader interventional portfolio.

Penumbra sells primarily to hospitals and healthcare systems that perform high-acuity interventional procedures...

  • Hospitals and health systemsprimary

    Buy devices for use in acute care and interventional suites where clot removal procedures are performed.

  • Specialist physiciansprimary

    Interventional neuroradiologists, neurologists, radiologists, cardiologists, and surgeons who use the products in procedures.

  • International distributorssecondary

    Buy and resell products in select markets where Penumbra does not sell entirely through direct teams.

  • Healthcare providers in emerging end marketssecondary

    Providers adopting thrombectomy and embolization therapies as clinical evidence and training expand.

Penumbra generates most of its revenue in the United States, with the balance coming from international markets...

  • •United States is the largest revenue market
  • •International sales are spread across Europe and other regions
  • •Direct sales coverage in the U.S., most of Europe, Canada, Australia, and Singapore
  • •Distributors are used in select international markets
  • •China is an important international exposure within the broader mix

Penumbra’s strategy centers on expanding its thrombectomy and interventional portfolio through product development,...

01
Expand the thrombectomy portfoliomedium-term

New and improved devices support adoption in stroke, PE, and limb ischemia.

02
Build clinical evidence and physician adoptionmedium-term

Specialist physicians need proof of efficacy and training before changing practice.

03
Expand manufacturing and supply capacityshort-term

Device demand requires reliable production, inventory, and facility footprint.

04
Grow international commercializationmedium-term

Broader geographic reach diversifies demand and extends the installed base.

Penumbra faces competitive, regulatory, and execution risks typical of medical device companies, including...

high

Supplier concentration and component shortages

Many materials and components come from a limited number of suppliers, with little guaranteed supply.

Scope
Manufacturing continuity and product availability
Materiality
high
high

Reimbursement and pricing pressure

Hospitals and payors may limit payment for medical devices through cost-control programs.

Scope
Procedure adoption and realized selling prices
Materiality
high
high

Competitive intensity

Large rivals have broader product lines, deeper relationships, and more resources.

Scope
Market share and physician adoption
Materiality
high
high

Acquisition uncertainty

Pending transaction uncertainty can affect customers, employees, and business execution.

Scope
Commercial continuity and strategic flexibility
Materiality
high
medium

IT and ERP implementation disruption

System changes can interrupt order tracking, shipping, supply chain, and financial data aggregation.

Scope
Operations and reporting reliability
Materiality
medium
Revenue recognition for product sales
Can shift quarterly revenue and comparability
Inventory and manufacturing estimates
Affects gross margin and working capital
Impairment and exit charges
Can materially affect operating income in the period recognized
ERP and internal control changes
May influence cut-off, controls, and reporting reliability

LivaNova PLC

LIVN · Electromedical & Electrotherapeutic Apparatus

BOSTON SCIENTIFIC CORP

BSX · Surgical & Medical Instruments & Apparatus

GLOBUS MEDICAL INC

GMED · Surgical & Medical Instruments & Apparatus

enVVeno Medical Corp

NVNO · Surgical & Medical Instruments & Apparatus

TriSalus Life Sciences, Inc.

TLSI · Surgical & Medical Instruments & Apparatus

ENvue Medical, Inc.

FEED · Orthopedic, Prosthetic & Surgical Appliances & Supplies

: 29/04/2026